FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149171909> ?p ?o ?g. }

• W2149171909 endingPage "1923" @default.
• W2149171909 startingPage "1915" @default.
• W2149171909 abstract "Abstract Purpose: This study aimed to determine a maximum tolerated dose (MTD) and recommended dose for disease-directed studies of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed at the epidermal growth factor receptor, and to characterize the safety profile, pharmacokinetics, preliminary antitumor activity, and immunogenicity of necitumumab. Experimental Design: Patients with advanced solid malignancies were treated with 100 to 1,000 mg (flat dosing) necitumumab followed by a 2-week pharmacokinetics sampling period, before beginning 6-week cycles of therapy. Results: Sixty patients received necitumumab weekly (29 patients) or every other week (31 patients). Two patients receiving 1,000 mg every 2 weeks experienced dose-limiting toxicities (DLT; grade 3 headache), accompanied by grade 3 nausea and vomiting in one patient. Occurring hours after the initial dose, these DLTs established 800 mg as the MTD. Mild dose-related skin toxicity was the most common drug-related toxicity (80%). One patient in each arm experienced grade 3 acneform rash, which responded to oral antibiotics and topical therapy. Toxicity was similar on both schedules. Necitumumab exhibited saturable elimination and nonlinear pharmacokinetics. At 800 mg (both arms), its half-life was approximately 7 days. All patients treated with ≥600 mg necitumumab achieved target trough concentrations (≥40 μg/mL). Antibodies against necitumumab were not detected. Partial response and stable disease were experienced by 2 and 16 patients, respectively. Conclusion: Well tolerated, necitumumab is associated with preliminary evidence of antitumor activity, and achieves biologically relevant concentrations throughout the dosing period. The recommended dose of necitumumab for further clinical development is 800 mg (flat dose) weekly or every 2 weeks based on the clinical setting. Clin Cancer Res; 16(6); 1915–23" @default.
• W2149171909 created "2016-06-24" @default.
• W2149171909 creator A5009004145 @default.
• W2149171909 creator A5011905014 @default.
• W2149171909 creator A5012285468 @default.
• W2149171909 creator A5022063365 @default.
• W2149171909 creator A5041653334 @default.
• W2149171909 creator A5043481012 @default.
• W2149171909 creator A5060207753 @default.
• W2149171909 creator A5065694446 @default.
• W2149171909 creator A5078972560 @default.
• W2149171909 creator A5089379108 @default.
• W2149171909 creator A5090649450 @default.
• W2149171909 date "2010-03-14" @default.
• W2149171909 modified "2023-10-18" @default.
• W2149171909 title "A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies" @default.
• W2149171909 cites W1553140736 @default.
• W2149171909 cites W1838340609 @default.
• W2149171909 cites W1892571469 @default.
• W2149171909 cites W1944107108 @default.
• W2149171909 cites W2005204942 @default.
• W2149171909 cites W2024992753 @default.
• W2149171909 cites W2035088306 @default.
• W2149171909 cites W2051120695 @default.
• W2149171909 cites W2064047613 @default.
• W2149171909 cites W2094703210 @default.
• W2149171909 cites W2139248078 @default.
• W2149171909 cites W2147304472 @default.
• W2149171909 cites W2149051154 @default.
• W2149171909 cites W2165183041 @default.
• W2149171909 cites W2260300870 @default.
• W2149171909 cites W2331056746 @default.
• W2149171909 cites W2337262864 @default.
• W2149171909 cites W2885572610 @default.
• W2149171909 cites W51995314 @default.
• W2149171909 doi "https://doi.org/10.1158/1078-0432.ccr-09-2425" @default.
• W2149171909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20197484" @default.
• W2149171909 hasPublicationYear "2010" @default.
• W2149171909 type Work @default.
• W2149171909 sameAs 2149171909 @default.
• W2149171909 citedByCount "70" @default.
• W2149171909 countsByYear W21491719092012 @default.
• W2149171909 countsByYear W21491719092013 @default.
• W2149171909 countsByYear W21491719092014 @default.
• W2149171909 countsByYear W21491719092015 @default.
• W2149171909 countsByYear W21491719092016 @default.
• W2149171909 countsByYear W21491719092017 @default.
• W2149171909 countsByYear W21491719092018 @default.
• W2149171909 countsByYear W21491719092019 @default.
• W2149171909 countsByYear W21491719092020 @default.
• W2149171909 countsByYear W21491719092021 @default.
• W2149171909 countsByYear W21491719092022 @default.
• W2149171909 countsByYear W21491719092023 @default.
• W2149171909 crossrefType "journal-article" @default.
• W2149171909 hasAuthorship W2149171909A5009004145 @default.
• W2149171909 hasAuthorship W2149171909A5011905014 @default.
• W2149171909 hasAuthorship W2149171909A5012285468 @default.
• W2149171909 hasAuthorship W2149171909A5022063365 @default.
• W2149171909 hasAuthorship W2149171909A5041653334 @default.
• W2149171909 hasAuthorship W2149171909A5043481012 @default.
• W2149171909 hasAuthorship W2149171909A5060207753 @default.
• W2149171909 hasAuthorship W2149171909A5065694446 @default.
• W2149171909 hasAuthorship W2149171909A5078972560 @default.
• W2149171909 hasAuthorship W2149171909A5089379108 @default.
• W2149171909 hasAuthorship W2149171909A5090649450 @default.
• W2149171909 hasBestOaLocation W21491719091 @default.
• W2149171909 hasConcept C112705442 @default.
• W2149171909 hasConcept C126322002 @default.
• W2149171909 hasConcept C2777288759 @default.
• W2149171909 hasConcept C2778570526 @default.
• W2149171909 hasConcept C2780580376 @default.
• W2149171909 hasConcept C2780852908 @default.
• W2149171909 hasConcept C29730261 @default.
• W2149171909 hasConcept C71924100 @default.
• W2149171909 hasConcept C90924648 @default.
• W2149171909 hasConcept C98274493 @default.
• W2149171909 hasConceptScore W2149171909C112705442 @default.
• W2149171909 hasConceptScore W2149171909C126322002 @default.
• W2149171909 hasConceptScore W2149171909C2777288759 @default.
• W2149171909 hasConceptScore W2149171909C2778570526 @default.
• W2149171909 hasConceptScore W2149171909C2780580376 @default.
• W2149171909 hasConceptScore W2149171909C2780852908 @default.
• W2149171909 hasConceptScore W2149171909C29730261 @default.
• W2149171909 hasConceptScore W2149171909C71924100 @default.
• W2149171909 hasConceptScore W2149171909C90924648 @default.
• W2149171909 hasConceptScore W2149171909C98274493 @default.
• W2149171909 hasIssue "6" @default.
• W2149171909 hasLocation W21491719091 @default.
• W2149171909 hasLocation W21491719092 @default.
• W2149171909 hasOpenAccess W2149171909 @default.
• W2149171909 hasPrimaryLocation W21491719091 @default.
• W2149171909 hasRelatedWork W1983907859 @default.
• W2149171909 hasRelatedWork W2004325424 @default.
• W2149171909 hasRelatedWork W2061178394 @default.
• W2149171909 hasRelatedWork W2087940120 @default.
• W2149171909 hasRelatedWork W2105212912 @default.
• W2149171909 hasRelatedWork W2243375749 @default.
• W2149171909 hasRelatedWork W2328289339 @default.

• next